Loading company…
ParcelBio develops programmable mRNA medicines using a targeted delivery platform.
Founded in 2024 and based in San Francisco, ParcelBio develops RNA-based drugs. Its Stabilized Targeted mRNA Platform stabilizes mRNA and uses an interchangeable targeting mechanism to deliver it to cell types throughout the body without nanoparticles. The company was co-founded by David Weinberg and Chris Carlson. In May 2026, it raised USD 13 million in seed funding led by Breyer Capital, with General Catalyst Partners, Y Combinator, Metaplanet Holdings, ZAKA, and SurgePoint Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in